Vycor Medical (VYCO) 10-Q 16 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 16, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	001-34932
Entity Registrant Name	VYCOR MEDICAL, INC
Entity Central Index Key	0001424768
Entity Tax Identification Number	20-3369218
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	951 Broken Sound Parkway
Entity Address, Address Line Two	Suite 320
Entity Address, City or Town	Boca Raton
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33487
City Area Code	(561)
Local Phone Number	558-2020
Title of 12(b) Security	Common Stock
Trading Symbol	VYCO
Entity Current Reporting Status	Yes
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		30,213,733

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Current Assets
Cash	$ 108,687	$ 46,002
Trade accounts receivable	205,087	159,238
Inventory	191,558	181,096
Prepaid expenses and other current assets	57,865	76,988
Current assets of discontinued operations	506	577
Total Current Assets	563,703	463,901
Fixed assets, net	387,062	381,087
Intangible and Other assets:
Patents, net of accumulated amortization	5,361	11,349
Security deposits	6,000	6,000
Operating lease - right of use assets	102,146	124,183
Total Intangible and Other assets	113,507	141,532
TOTAL ASSETS	1,064,272	986,520
Current Liabilities
Accounts payable	217,950	179,110
Accrued interest: Other	358,677	328,897
Accrued interest: Related party	90,268	74,603
Accrued liabilities - Other	128,342	117,050
Accrued liabilities - Related Party	1,459,665	1,297,480
Notes payable: Other	417,200	384,587
Notes payable: Related Party	320,873	310,873
Current operating lease liabilities	45,746	44,623
Current liabilities of discontinued operations	(76)	3,605
Total Current Liabilities	3,038,645	2,740,828
Loan Payable - SBA EIDL	150,000	150,000
Operating lease liability - Long term	54,395	77,008
Total Long-term Liabilities	204,395	227,008
STOCKHOLDERS’ DEFICIENCY
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, 270,307 and 270,307 issued and outstanding as at June 30, 2021 and December 31, 2020 respectively	27	27
Common Stock, $0.0001 par value, 55,000,000 shares authorized at June 30, 2021 and December 31, 2020, 30,317,067 and 27,534,740 shares issued and 30,213,733 and 27,431,406 outstanding at June 30, 2021 and December 31, 2020 respectively	3,032	2,753
Additional Paid-in Capital	29,043,123	28,826,378
Treasury Stock (103,334 shares of Common Stock as at June 30, 2021 and December 31, 2020 respectively, at cost)	(1,033)	(1,033)
Accumulated Deficit	(31,351,588)	(30,937,110)
Accumulated Other Comprehensive Income	127,671	127,669
Total Stockholders’ Deficiency	(2,178,768)	(1,981,316)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIENCY	$ 1,064,272	$ 986,520

Consolidated Balance Sheets (_2

Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	270,307	270,307
Preferred stock, shares outstanding	270,307	270,307
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	55,000,000	55,000,000
Common stock, shares issued	30,317,067	27,534,740
Common stock, shares outstanding	30,213,733	27,431,406
Treasury stock, shares	103,334	103,334

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue from Contract with Customer [Abstract]
Revenue	$ 491,427	$ 244,266	$ 787,176	$ 574,505
Cost of Goods Sold	39,328	20,493	67,805	57,787
Gross Profit	452,099	223,773	719,371	516,718
Operating Expenses:
Research and development	3,929		6,629
Depreciation and amortization	17,602	14,643	31,547	29,285
Selling, general and administrative	407,079	408,488	864,555	833,492
Total Operating Expenses	428,610	423,131	902,731	862,777
Operating income (loss)	23,489	(199,358)	(183,360)	(346,059)
Other Income (Expense)
Interest expense: Related Party	(8,000)	(7,586)	(15,665)	(14,010)
Interest expense: Other	(13,662)	(11,967)	(29,780)	(23,934)
Loss on foreign currency exchange	(884)	(224)	(999)	(345)
Total Other Income (Expense)	(22,546)	(19,777)	(46,444)	(38,289)
Income (Loss) Before Credit for Income Taxes	943	(219,135)	(229,804)	(384,348)
Credit for income taxes
Net Income (Loss) from continuing operations	943	(219,135)	(229,804)	(384,348)
Loss from discontinued operations, net of tax	(10,317)	(29,752)	(22,489)	(39,487)
Net Loss	(9,374)	(248,887)	(252,293)	(423,835)
Preferred stock dividends			(162,185)	(162,185)
Net Loss Available to Common Stockholders	(9,374)	(248,887)	(414,478)	(586,020)
Other Comprehensive Loss
Foreign Currency Translation Adjustment	(5)		2	2
Comprehensive Loss	$ (9,379)	$ (248,887)	$ (252,291)	$ (423,833)
Net Income (Loss) Per Share - basic and diluted
Income (Loss) from continuing operations	$ 0	$ (0.01)	$ (0.01)	$ (0.02)
Loss from discontinued operations	0	0	0	0
Net loss available to common stockholders	$ 0	$ (0.01)	$ (0.01)	$ (0.02)
Weighted Average Number of Shares Outstanding – Basic and Diluted	29,670,235	25,830,151	28,755,966	25,562,295

Consolidated Statement of Stock

Consolidated Statement of Stockholders' Deficiency (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Balance at December 31, 2019	$ (2,263,983)	$ (1,558,094)	$ (1,981,316)	$ (1,354,463)
Issuance of stock for board and consulting fees	94,594	112,499	196,024	224,999
Directors deferred compensation granted		21,000	21,000	42,000
Issuance of stock related to deferred compensation of directors
Issuance of shares pursuant to exercise of warrants
Accumulated Comprehensive Loss	(5)		2	2
Net loss for period available to common stockholders	(9,374)	(248,887)	(414,478)	(586,020)
Balance at June 30, 2020	(2,178,768)	(1,673,482)	(2,178,768)	(1,673,482)
Common Stock [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Balance at December 31, 2019	$ 2,854	$ 2,593	$ 2,753	$ 2,539
Balance, shares	28,537,248	25,927,598	27,534,740	25,391,884
Issuance of stock for board and consulting fees	$ 64	$ 53	$ 118	$ 107
Issuance of stock for board and consulting fees, shares	637,377	535,714	1,173,091	1,071,428
Issuance of stock related to deferred compensation of directors	$ 114		$ 161
Issuance of stock related to deferred compensation of directors, shares	1,142,442		1,609,236
Balance at June 30, 2020	$ 3,032	$ 2,646	$ 3,032	$ 2,646
Balance, shares	30,317,067	26,463,312	30,317,067	26,463,312
Preferred C [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Balance at December 31, 2019	$ 0	$ 0	$ 0	$ 0
Balance, shares	1	1	1	1
Issuance of stock for board and consulting fees
Issuance of stock for board and consulting fees, shares
Issuance of stock related to deferred compensation of directors
Issuance of stock related to deferred compensation of directors, shares
Balance at June 30, 2020	$ 0	$ 0	$ 0	$ 0
Balance, shares	1	1	1	1
Preferred D [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Balance at December 31, 2019	$ 27	$ 27	$ 27	$ 27
Balance, shares	270,306	270,306	270,306	270,306
Issuance of stock for board and consulting fees
Issuance of stock for board and consulting fees, shares
Issuance of stock related to deferred compensation of directors
Issuance of stock related to deferred compensation of directors, shares
Balance at June 30, 2020	$ 27	$ 27	$ 27	$ 27
Balance, shares	270,306	270,306	270,306	270,306
Treasury Stock [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Balance at December 31, 2019	$ (1,033)	$ (1,033)	$ (1,033)	$ 1,033
Balance, shares	(103,334)	(103,334)	(103,334)	(103,334)
Issuance of stock for board and consulting fees
Issuance of stock for board and consulting fees, shares
Issuance of stock related to deferred compensation of directors
Issuance of stock related to deferred compensation of directors, shares
Balance at June 30, 2020	$ (1,033)	$ (1,033)	$ (1,033)	$ (1,033)
Balance, shares	(103,334)	(103,334)	(103,334)	(103,334)
Additional Paid-in Capital [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Balance at December 31, 2019	$ 28,948,707	$ 28,440,038	$ 28,826,378	$ 28,306,592
Issuance of stock for board and consulting fees	94,530	112,446	195,906	224,892
Directors deferred compensation granted		21,000	21,000	42,000
Issuance of stock related to deferred compensation of directors	(114)		(161)
Balance at June 30, 2020	29,043,123	28,573,484	29,043,123	28,573,484
Retained Earnings [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Balance at December 31, 2019	(31,342,214)	(30,127,391)	30,937,110	(29,790,258)
Issuance of shares pursuant to exercise of warrants
Net loss for period available to common stockholders	(9,374)	(248,887)	(414,478)	(586,020)
Balance at June 30, 2020	(31,351,588)	(30,376,278)	(31,351,588)	(30,376,278)
AOCI Attributable to Parent [Member]
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Balance at December 31, 2019	127,676	127,672	127,669	127,670
Issuance of shares pursuant to exercise of warrants
Accumulated Comprehensive Loss	(5)		2	2
Balance at June 30, 2020	$ 127,671	$ 127,672	$ 127,671	$ 127,672

Consolidated Statement of Cash

Consolidated Statement of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net loss	$ (252,293)	$ (423,835)
Adjustments to reconcile net loss to cash provided by (used in) operating activities:
Amortization of intangible assets	5,988	5,988
Depreciation of fixed assets	26,267	24,381
Inventory provision	6,180	6,279
Stock based compensation	201,927	266,999
Changes in assets and liabilities:
Accounts receivable	(45,849)	177,587
Inventory	(16,642)	8,454
Prepaid expenses	34,766	17,359
Accrued interest - Related Party	15,665	14,011
Accrued interest - Other	29,780	23,934
Accounts payable	38,840	(74,838)
Accrued liabilities - Other	11,292	(125,921)
Changes in discontinued operations, net	(3,610)	473
Cash provided by (used in) operating activities	52,311	(79,129)
Cash flows from investing activities:
Purchase of fixed assets	(32,242)	(49,991)
Changes in investing activities of discontinued operations, net		(376)
Cash used in investing activities	(32,242)	(50,367)
Cash flows from financing activities:
Proceeds from Notes Payable - Related Party	10,000	80,000
Proceeds from Paycheck Protection Program	58,600	58,600
Proceeds net of repayments Notes Payable - Other	(25,987)	1,172
Cash provided by financing activities	42,613	139,772
Effect of exchange rate changes on cash	3	1
Net increase in cash	62,685	10,277
Cash at beginning of period	46,002	60,717
Cash at end of period	108,687	70,994
Supplemental Disclosures of Cash Flow information:
Cash paid for interest
Cash paid for income tax

BASIS OF PRESENTATION

BASIS OF PRESENTATION	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	1. BASIS OF PRESENTATION The accompanying unaudited consolidated financial statements of Vycor Medical, Inc. (the “Company” or “Vycor”) have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X of the Securities Exchange Commission. In accordance with those rules and regulations certain information and footnote disclosures normally included in consolidated financial statements have been omitted pursuant to such rules and regulations. The consolidated balance sheet as of December 31, 2020 derives from the audited financial statements at that date, but does not include all the information and footnotes required by GAAP. These unaudited consolidated financial statements should be read in conjunction with the audited financial statements and notes thereto included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020. The unaudited consolidated financial statements as of and for the three and six months ended June 30, 2021 and 2020, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of the Company’s financial condition, results of operations and cash flows. The results of operations for the three and six months ended June 30, 2021 and 2020 are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Ability to continue as a Going Concern The accompanying unaudited consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has incurred losses since its inception, including a net loss of $ 252,293 604,136 1,870,806 The Company is executing on a plan to achieve a reduction in cash operating losses. Included within the working capital deficiency above is a term note for $ 300,000 352,699 October 15, 2021

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
SIGNIFICANT ACCOUNTING POLICIES	2. SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation The unaudited consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company account balances, transactions, and profits have been eliminated in consolidation. Following the decision in April 2020 to close the German office of NovaVision, the activities of NovaVision GmbH have been accounted for as discontinued operations. Recent Accounting Pronouncements From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented. Discontinued Operations In accordance with ASU No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the components of an entity meets the criteria in paragraph 205-20-45-1E to be classified as held for sale. When all of the criteria to be classified as held for sale are met, including management, having the authority to approve the action, commits to a plan to sell the entity, the major current assets, other assets, current liabilities, and noncurrent liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations (which we presented as operations to be disposed and operations disposed), less applicable income taxes (benefit), shall be reported as components of net income (loss) separate from the net income (loss) of continuing operations in accordance with ASC 205-20-45. Accounting for forgivable loan received under the Small Business Administration Paycheck Protection Program During the year ended December 31, 2020 the Company received a loan of $ 58,600 58,600 The Company accounts for the loans as a financial liability in accordance with FASB ASC 470 and accrues interest in accordance with the interest method under FASB ASC 835-30. For purposes of derecognition of the liability, FASB ASC 470-50-15-4 refers to guidance in FASB ASC 405-20. Based on this guidance, the proceeds of the loans will remain recorded as a liability until either (1) the loans are, in part or wholly, forgiven and the Company has been “legally released”, or (2) the Company pays off the loans. Once the loans are, in part or wholly, forgiven and legal release is received, the Company will reduce the liability by the amount forgiven and record a gain on the extinguishment. Net Loss Per Share Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive. The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share: SCHEDULE OF COMMON STOCK NOT INCLUDED IN CALCULATION OF DILUTED NET LOSS PER SHARE June 30, 2021 June 30, 2020 Stock options outstanding - 680,000 Debentures convertible into common stock 3,108,092 2,879,521 Preferred shares convertible into common stock 1,272,052 1,272,052 Directors Deferred Compensation Plan - 1,375,905 Total 4,380,144 6,207,478 Covid-19 Vycor Medical experienced a significant reduction in demand during the twelve months ended December 31, 2020 in the US and Europe, particularly in the second quarter, with some recovery in the third and fourth quarters. This recovery continued during the three months ended March 31, 2021 and with a much stronger level of recovery during the three months ended June 30, 2021 such that sales for the Vycor Medical division increased by 38% over the same period in 2020. Although neurosurgery is not considered an elective procedure, general hospital dislocation and diversion of resources away from non-emergency surgeries, or surgeries that can be postponed for a short period without harm, has impacted our revenues during the twelve months ended December 31, 2020 and although this has recovered during the six months ended June 30, 2021, COVID-19 remains clasified as a pandemic and this could impact future sales. In addition, sales and marketing efforts by Vycor’s representatives were disrupted or curtailed during periods of lockdown and social distancing, and this may continue to hinder the recovery of revenues, particularly in certain international territories where vaccination rates remain relatively low. While our operations are principally located in the United States, and our sub-contract manufacturers are located in the United States, we participate in a global supply chain, and COVID-19 may impact our ability to conduct normal business operations, which could adversely affect our results of operations and liquidity. Furthermore, our sub-contract manufacturers have experienced staffing shortages and this has elongated our production lead times. Disruptions to our supply chain and business operations, or to our suppliers’ or customers’ supply chains and business operations, could include disruptions from supplier staff absences due to COVID-19 illness or isolation requirements, the closure of supplier and manufacturer facilities, interruptions in the supply of raw materials and components, or restrictions on the shipment of our or our suppliers’ or customers’ products, any of which could have adverse ripple effects on our manufacturing output and delivery schedule. Although we have implemented business continuity plans for our offices and personnel to enable continuity of service remotely if required, if a critical number of our employees become too ill to work, or we are not able to access a sufficient quantity of our inventory for shipment due to enforced office closures, our production ability could be materially adversely affected in a rapid manner. Similarly, if our customers experience adverse business consequences due to COVID-19, or any other, pandemic, demand for our products could also be materially adversely affected in a rapid manner. Global health concerns, such as COVID-19, could also result in social, economic, and labor instability in the countries and localities in which we or our suppliers and customers operate. Any of these uncertainties could have a material adverse effect on our business, financial condition or results of operations.

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	6 Months Ended
	Jun. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	3. DISCONTINUED OPERATIONS In April 2020, the board of Vycor took the decision to close the German operations of NovaVision, including the German office and NovaVision GmbH, and instead migrate to a licensed business model; in June 2020 Vycor announced that it would be entering into a license agreement and transition agreement (the “Agreements”) with HelferApp GmbH, a cognitive therapy specialist. Under the Agreements, HelferApp is licensed to provide NovaVision’s products and therapies in Germany, Austria and Switzerland to patients and professionals; and has assumed responsibility for the current patients of NovaVision in the territory. The NovaVision German office was closed effective June 30, 2020. The Company will continue to fund the remaining expenses of the German operations, which are non-material, until such a time as NovaVision GmbH is formally wound up. Reconciliation of the major line items from discontinued operations that are presented in the unaudited consolidated balance sheets and unaudited consolidated statements of comprehensive loss are as follows: Major line items constituting assets and liabilities in the unaudited consolidated balance sheets SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS June 30, 2021 December 31, 2020 ASSETS Current Assets Cash $ 506 $ 577 Total Current Assets 506 577 TOTAL ASSETS $ 506 $ 577 LIABILITIES Current Liabilities Accounts payable $ 134 $ 422 Accrued liabilities - Other - 3,168 Other current liabilities (210 ) 15 Total Current Liabilities $ (76 ) $ 3,605 Major line items constituting loss from discontinued operations 2021 2020 2021 2020 For the three months ended For the six months ended 2021 2020 2021 2020 Revenue $ - $ 17,864 $ - $ 38,676 Cost of Goods Sold - 2,618 - 4,219 Gross Profit - 15,246 - 34,457 Operating Expenses: Selling, general and administrative 10,078 43,780 21,647 72,682 Total Operating Expenses (10,078 ) (43,780 ) (21,647 ) (72,682 ) Operating Loss (10,078 ) (28,534 ) (21,647 ) (38,225 ) Other Income (Expense) Loss on foreign currency exchange (239 ) (1,218 ) (842 ) (1,262 ) Total Other Income (Expense) (239 ) (1,218 ) (842 ) (1,262 ) Loss Before Credit for Income Taxes (10,317 ) (29,752 ) (22,489 ) (39,487 ) Credit for income taxes - - - - Loss from discontinued operations, net of tax $ (10,317 ) $ (29,752 ) $ (22,489 ) $ (39,487 )

NOTES PAYABLE

NOTES PAYABLE	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
NOTES PAYABLE	4. NOTES PAYABLE Related Parties Notes Payable Related Party Notes Payable consists of: SUMMARY OF NOTES PAYABLE June 30, 2021 December 31, 2020 On June 25, 2018 the Company issued promissory notes to Peter Zachariou for $ 30,000 10 June 25, 2022 $ 30,000 $ 30,000 Between March 26, 2018 and March 12, 2021 the Company issued eleven promissory notes to Fountainhead Capital Management Limited for $ 290,873 10 The Notes will be due between December 2021 and July 2022 or on demand by the Payee. 290,873 280,873 Total Related Party Notes Payable $ 320,873 $ 310,873 Other Notes Payable Other Notes Payable consists of: June 30, 2021 December 31, 2020 On March 25, 2011 the Company issued a term note for $ 300,000 16 June 25, 2011 October 15, 2021 $ 300,000 $ 300,000 On May 16, 2020, the Company was granted a loan from Citizens Bank N.A. in the amount of $ 58,600 The Loan, which was in the form of a Note issued by the Borrower, matures on May 16, 2022 1 58,600 58,600 On January 1, 2021, the Company was granted a second PPP loan from Citizens Bank N.A. in the amount of $ 58,600 The Loan, which was in the form of a Note issued by the Borrower, matures on January 1, 2026 1 58,600 - Insurance policy finance agreements. - 25,987 Total Notes Payable: $ 417,200 $ 384,587 Long-Term Notes Payable consists of: June 30, 2021 December 31, 2020 On July 7, 2020, the Company was advised that the Small Business Administration (SBA) had approved a $ 150,000 30 3.75 731.00 $ 150,000 $ 150,000 Total Long-Term Notes Payable: $ 150,000 $ 150,000 In January 2018 the Company entered into an amendment agreement (the “Amendment”) with EuroAmerican Investments (“EuroAmerican”) regarding its $ 300,000 0.21 3,108,092 The Company routinely finances all their insurance policies through a third party finance company which requires a down payment and subsequent monthly payments, the time periods vary from 10 months to 12 equal monthly payments.

LEASE

LEASE	6 Months Ended
	Jun. 30, 2021
Lease
LEASE	5. LEASE The Company recognized the following related to a lease in its unaudited consolidated balance sheet at June 30, 2021 and December 31, 2020: SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES June 30, 2021 December 31, 2020 Operating Lease ROU Assets $ 102,146 $ 124,183 Operating Lease ROU Assets $ 102,146 $ 124,183 Operating Lease Liabilities Current portion 45,746 44,623 Long-term portion $ 54,395 $ 77,008 Operating Lease Liabilities $ 100,141 $ 121,631

SEGMENT REPORTING, GEOGRAPHICAL

SEGMENT REPORTING, GEOGRAPHICAL INFORMATION	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
SEGMENT REPORTING, GEOGRAPHICAL INFORMATION	6. SEGMENT REPORTING, GEOGRAPHICAL INFORMATION (a) Business segments The Company operates in two business segments SCHEDULE OF BUSINESS SEGMENTS INFORMATION Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Revenue: Vycor Medical $ 462,318 $ 218,997 $ 725,032 $ 526,284 NovaVision $ 29,109 $ 25,269 $ 62,144 $ 48,221 $ 491,427 $ 244,266 $ 787,176 $ 574,505 Gross Profit Vycor Medical $ 424,261 $ 201,179 $ 660,194 $ 472,036 NovaVision $ 27,838 $ 22,594 $ 59,177 $ 44,682 $ 452,099 $ 223,773 $ 719,371 $ 516,718 June 30, December 31, 2021 2020 Total Assets: Vycor Medical $ 1,036,954 $ 953,730 NovaVision 26,812 32,213 Discontinued operations 506 577 Total Assets $ 1,064,272 $ 986,520 (b) Geographic information The Company operates in two geographic segments, the United States and Europe. Discontinued operations were part of NovaVision and revenues and assets were in Europe; see Note 3. Set out below are the revenues, gross profits and total assets for each segment. SUMMARY OF GEOGRAPHIC INFORMATION Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Revenue: United States $ 487,908 $ 241,325 $ 776,689 $ 569,140 Europe $ 3,519 $ 2,941 $ 10,487 $ 5,365 $ 491,427 $ 244,266 $ 787,176 $ 574,505 Gross Profit United States $ 448,611 $ 220,832 $ 708,982 $ 511,353 Europe $ 3,488 $ 2,941 $ 10,389 $ 5,365 $ 452,099 $ 223,773 $ 719,371 $ 516,718 June 30, December 31, 2021 2020 Total Assets: United States $ 1,054,002 $ 980,239 Europe 9,764 5,704 Discontinued operations 506 577 Total Assets $ 1,064,272 $ 986,520

EQUITY

EQUITY	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
EQUITY	7. EQUITY Common Stock Grants During January to June 2021 and 2020, the Company granted 99,999 shares of Common Stock (valued at $ 21,000 ) and 199,998 shares of Common Stock (valued at $ 42,000 ), respectively, to non-employee Directors. Under the terms of the Directors Deferred Compensation Plan, the receipt of these shares is deferred until the January 15 th 575,649 and 566,793 shares of common stock to Steve Girgenti and Lowell Rush in respect of their Deferred Compensation shares following their resignations from the board. In January 2021 the Company issued 466,794 On April 1, 2021 the Company issued 101,663 During January to June 2021 and 2020, under the terms of the Consulting Agreement referred to in note 10, the Company issued 1,071,428 175,895 225,000 Stock Options The details of the outstanding stock options are as follows: SCHEDULE OF STOCK OPTIONS Weighted average Number of shares exercise price Outstanding at December 31, 2020 680,000 $ 0.28 Granted - - Exercised - - Cancelled or expired (680,000 ) - Outstanding at June 30, 2021 - $ -

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Jun. 30, 2021
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	8. STOCK-BASED COMPENSATION The Company from time to time issues common stock, stock options or common stock warrants to acquire services or goods from non-employees. Common stock, stock options and common stock warrants issued to other than employees or directors are recorded on the basis of their fair value, which is measured as of the “measurement date” using an option pricing model, or their contractual value if different in the case of common stock. The “measurement date” for options and warrants related to contracts that have substantial disincentives to non-performance is the date of the contract, and for all other contracts is the vesting date. Expense related to the options and warrants is recognized on a straight-line basis over the shorter of the period over which services are to be received or the life of the option or warrant. Non-Employee Stock Compensation Aggregate stock-based compensation for stock granted to non-employees for each of the six months ended June 30, 2021 and 2020 was $ 201,927 and $ 266,999 , respectively. The expense related to stock not issued during each of the six months ended June 30, 2021 and 2020 comprises $ 0 and $ 42,000 , respectively, related to stock granted but not issued to directors under the Directors Deferred Compensation Plan. As of June 30, 2021, there was $ 0 of total unrecognized compensation costs related to warrant and stock awards and non-vested options.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Jun. 30, 2021
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	9. COMMITMENTS AND CONTINGENCIES Lease The Company leases office space located at 951 Broken Sound Parkway, Suite 320, Boca Raton, FL 33487 from WPT Land 2 L.P., for a gross rent of approximately $ 4,000 1,500 The lease terminated September 30, 2020 and was extended for a further three years to August 31, 2023. 1,650 1,815 38,954 39,349 Potential German tax liability In June 2012 the Company’s NovaVision German subsidiary received a preliminary assessment for Magdeburg City trade tax of € 75,000 82,000 12,000 13,200 75,000 82,000 12,000 13,200

CONSULTING AND OTHER AGREEMENTS

CONSULTING AND OTHER AGREEMENTS	6 Months Ended
	Jun. 30, 2021
Consulting And Other Agreements
CONSULTING AND OTHER AGREEMENTS	10. CONSULTING AND OTHER AGREEMENTS The following agreements were entered into or remained in force during the period ended June 30, 2021: Consulting Agreement with Fountainhead Effective January 1, 2021, the Company made a slight amendment to the Fountainhead Consulting Agreement (“the Amended Agreement”). Under the Amended Agreement, fees are payable to Fountainhead, with an option to receive $ 5,000 535,714 0.21 112,500 During the six months ended June 30, 2021 and June 30, 2020, under the terms of the Amended Agreement, Fountainhead received 1,071,428 175,895 225,000 On March 30, 2021, Vycor entered into a Consulting Agreement with Ricardo J. Komotar, M.D. (the “Agreement”) to provide certain specified services over the three-year term of the Agreement. Under the Agreement, Dr. Komotar will provide general scientific advisory consultancy services, and will also provide scientific advisory services based around certain specific pre-determined milestones. In consideration of the Consultant’s services, the Company agreed to deliver to the Consultant over the course of the three-year term, a total of 304,989 1,219,957 101,663

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	11. RELATED PARTY TRANSACTIONS Peter Zachariou and David Cantor, directors of the Company, are investment managers of Fountainhead, which owned, at June 30, 2021, 58.6 % of the Company’s Common Stock and 70 % of the Company’s Preferred D Stock. Peter Zachariou owns 26 % of the Company’s Preferred D Stock. Adrian Liddell, Chairman, is a consultant for Fountainhead. During each of the six months ended June 30, 2021 and June 30, 2020, under the terms of the Amended Agreement referred to in note 10, the Company issued 1,071,428 shares of Common Stock to Fountainhead valued at $ 175,895 and $ 225,000 , respectively. During each of the six months ended June 30, 2021 and 2020, the Company accrued an aggregate of $ 162,185 113,019 41,693 During the six months ended June 30, 2021 and 2020 the Company issued unsecured loan notes to Fountainhead for a total of $ 10,000 80,000 10 due on demand or by their one-year anniversary There were no

CONCENTRATION

CONCENTRATION	6 Months Ended
	Jun. 30, 2021
Risks and Uncertainties [Abstract]
CONCENTRATION	12. CONCENTRATION Vycor Medical sells its neurosurgical devices in the US primarily direct to hospitals, and internationally through distributors who in turn sell to hospitals. SCHEDULE OF CONCENTRATION Sales Concentration: Three Months Ended June 30, 2021 2020 Number of customers over 10% - - Percentage of sales 0 % 0 % Six Months Ended June 30, 2021 2020 Number of customers over 10% - 1 Percentage of sales 0 % 19 % Accounts Receivable Concentration At June 30, At December 31, 2021 2020 Number of customers over 10% 0 2 Percentage of accounts receivable 0 % 10 % The Company has three sub-contract manufacturers from which it purchases, respectively, VBAS injection molded parts, completed and sterilized VBAS units, and VBAS extension arms. Purchases from these manufacturers vary from quarter to quarter, with no purchases in some quarters, however on an annual basis purchases from each manufacturer represent over 10

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	13. SUBSEQUENT EVENTS The Company has evaluated the existence of events and transactions subsequent to the balance sheet date through the date the unaudited consolidated financial statements were issued and has determined that there were no significant subsequent events or transactions which would require recognition or disclosure in the financial statements.

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The unaudited consolidated financial statements include the accounts of Vycor Medical, Inc., and its wholly-owned subsidiaries, NovaVision, Inc. (a Delaware corporation), NovaVision GmbH (a German corporation) and Sight Science Limited (a UK corporation), both wholly owned subsidiaries of NovaVision, Inc. The Company is headquartered in Boca Raton, FL. All material inter-company account balances, transactions, and profits have been eliminated in consolidation. Following the decision in April 2020 to close the German office of NovaVision, the activities of NovaVision GmbH have been accounted for as discontinued operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements From time to time new accounting pronouncements are issued by the Financial Accounting Standards Board or other standard setting bodies that may have an impact on the Company’s accounting and reporting. The Company believes that recently issued accounting pronouncements and other authoritative guidance for which the effective date is in the future will not have an impact on its accounting or reporting or that such impact will not be material to its financial position, results of operations and cash flows when implemented.
Discontinued Operations	Discontinued Operations In accordance with ASU No. 2014-08, Reporting Discontinued Operations and Disclosures of Disposals of Components of an Entity, a disposal of a component of an entity or a group of components of an entity is required to be reported as discontinued operations if the disposal represents a strategic shift that has (or will have) a major effect on an entity’s operations and financial results when the components of an entity meets the criteria in paragraph 205-20-45-1E to be classified as held for sale. When all of the criteria to be classified as held for sale are met, including management, having the authority to approve the action, commits to a plan to sell the entity, the major current assets, other assets, current liabilities, and noncurrent liabilities shall be reported as components of total assets and liabilities separate from those balances of the continuing operations. At the same time, the results of all discontinued operations (which we presented as operations to be disposed and operations disposed), less applicable income taxes (benefit), shall be reported as components of net income (loss) separate from the net income (loss) of continuing operations in accordance with ASC 205-20-45.
Accounting for forgivable loan received under the Small Business Administration Paycheck Protection Program	Accounting for forgivable loan received under the Small Business Administration Paycheck Protection Program During the year ended December 31, 2020 the Company received a loan of $ 58,600 58,600 The Company accounts for the loans as a financial liability in accordance with FASB ASC 470 and accrues interest in accordance with the interest method under FASB ASC 835-30. For purposes of derecognition of the liability, FASB ASC 470-50-15-4 refers to guidance in FASB ASC 405-20. Based on this guidance, the proceeds of the loans will remain recorded as a liability until either (1) the loans are, in part or wholly, forgiven and the Company has been “legally released”, or (2) the Company pays off the loans. Once the loans are, in part or wholly, forgiven and legal release is received, the Company will reduce the liability by the amount forgiven and record a gain on the extinguishment.
Net Loss Per Share	Net Loss Per Share Basic net loss per share is computed by dividing net loss available to common stockholders by the weighted-average number of common shares outstanding during the period. Diluted net loss per share is computed giving effect to all dilutive potential common shares that were outstanding during the period. Dilutive potential common shares consist of incremental shares issuable upon exercise of stock options and warrants and conversion of preferred stock and convertible debt. Such potentially dilutive shares are excluded when the effect would be to reduce a net loss per share. No dilution adjustment has been made to the weighted average outstanding common shares in the periods presented because the assumed exercise of outstanding options and warrants and the conversion of preferred stock and debt would be anti-dilutive. The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share: SCHEDULE OF COMMON STOCK NOT INCLUDED IN CALCULATION OF DILUTED NET LOSS PER SHARE June 30, 2021 June 30, 2020 Stock options outstanding - 680,000 Debentures convertible into common stock 3,108,092 2,879,521 Preferred shares convertible into common stock 1,272,052 1,272,052 Directors Deferred Compensation Plan - 1,375,905 Total 4,380,144 6,207,478
Covid-19	Covid-19 Vycor Medical experienced a significant reduction in demand during the twelve months ended December 31, 2020 in the US and Europe, particularly in the second quarter, with some recovery in the third and fourth quarters. This recovery continued during the three months ended March 31, 2021 and with a much stronger level of recovery during the three months ended June 30, 2021 such that sales for the Vycor Medical division increased by 38% over the same period in 2020. Although neurosurgery is not considered an elective procedure, general hospital dislocation and diversion of resources away from non-emergency surgeries, or surgeries that can be postponed for a short period without harm, has impacted our revenues during the twelve months ended December 31, 2020 and although this has recovered during the six months ended June 30, 2021, COVID-19 remains clasified as a pandemic and this could impact future sales. In addition, sales and marketing efforts by Vycor’s representatives were disrupted or curtailed during periods of lockdown and social distancing, and this may continue to hinder the recovery of revenues, particularly in certain international territories where vaccination rates remain relatively low. While our operations are principally located in the United States, and our sub-contract manufacturers are located in the United States, we participate in a global supply chain, and COVID-19 may impact our ability to conduct normal business operations, which could adversely affect our results of operations and liquidity. Furthermore, our sub-contract manufacturers have experienced staffing shortages and this has elongated our production lead times. Disruptions to our supply chain and business operations, or to our suppliers’ or customers’ supply chains and business operations, could include disruptions from supplier staff absences due to COVID-19 illness or isolation requirements, the closure of supplier and manufacturer facilities, interruptions in the supply of raw materials and components, or restrictions on the shipment of our or our suppliers’ or customers’ products, any of which could have adverse ripple effects on our manufacturing output and delivery schedule. Although we have implemented business continuity plans for our offices and personnel to enable continuity of service remotely if required, if a critical number of our employees become too ill to work, or we are not able to access a sufficient quantity of our inventory for shipment due to enforced office closures, our production ability could be materially adversely affected in a rapid manner. Similarly, if our customers experience adverse business consequences due to COVID-19, or any other, pandemic, demand for our products could also be materially adversely affected in a rapid manner. Global health concerns, such as COVID-19, could also result in social, economic, and labor instability in the countries and localities in which we or our suppliers and customers operate. Any of these uncertainties could have a material adverse effect on our business, financial condition or results of operations.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
SCHEDULE OF COMMON STOCK NOT INCLUDED IN CALCULATION OF DILUTED NET LOSS PER SHARE	The following table sets forth the potential shares of common stock that are not included in the calculation of diluted net loss per share: SCHEDULE OF COMMON STOCK NOT INCLUDED IN CALCULATION OF DILUTED NET LOSS PER SHARE June 30, 2021 June 30, 2020 Stock options outstanding - 680,000 Debentures convertible into common stock 3,108,092 2,879,521 Preferred shares convertible into common stock 1,272,052 1,272,052 Directors Deferred Compensation Plan - 1,375,905 Total 4,380,144 6,207,478

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	6 Months Ended
	Jun. 30, 2021
Discontinued Operations and Disposal Groups [Abstract]
SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS	Reconciliation of the major line items from discontinued operations that are presented in the unaudited consolidated balance sheets and unaudited consolidated statements of comprehensive loss are as follows: Major line items constituting assets and liabilities in the unaudited consolidated balance sheets SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS June 30, 2021 December 31, 2020 ASSETS Current Assets Cash $ 506 $ 577 Total Current Assets 506 577 TOTAL ASSETS $ 506 $ 577 LIABILITIES Current Liabilities Accounts payable $ 134 $ 422 Accrued liabilities - Other - 3,168 Other current liabilities (210 ) 15 Total Current Liabilities $ (76 ) $ 3,605 Major line items constituting loss from discontinued operations 2021 2020 2021 2020 For the three months ended For the six months ended 2021 2020 2021 2020 Revenue $ - $ 17,864 $ - $ 38,676 Cost of Goods Sold - 2,618 - 4,219 Gross Profit - 15,246 - 34,457 Operating Expenses: Selling, general and administrative 10,078 43,780 21,647 72,682 Total Operating Expenses (10,078 ) (43,780 ) (21,647 ) (72,682 ) Operating Loss (10,078 ) (28,534 ) (21,647 ) (38,225 ) Other Income (Expense) Loss on foreign currency exchange (239 ) (1,218 ) (842 ) (1,262 ) Total Other Income (Expense) (239 ) (1,218 ) (842 ) (1,262 ) Loss Before Credit for Income Taxes (10,317 ) (29,752 ) (22,489 ) (39,487 ) Credit for income taxes - - - - Loss from discontinued operations, net of tax $ (10,317 ) $ (29,752 ) $ (22,489 ) $ (39,487 )

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	6 Months Ended
	Jun. 30, 2021
Debt Disclosure [Abstract]
SUMMARY OF NOTES PAYABLE	Related Party Notes Payable consists of: SUMMARY OF NOTES PAYABLE June 30, 2021 December 31, 2020 On June 25, 2018 the Company issued promissory notes to Peter Zachariou for $ 30,000 10 June 25, 2022 $ 30,000 $ 30,000 Between March 26, 2018 and March 12, 2021 the Company issued eleven promissory notes to Fountainhead Capital Management Limited for $ 290,873 10 The Notes will be due between December 2021 and July 2022 or on demand by the Payee. 290,873 280,873 Total Related Party Notes Payable $ 320,873 $ 310,873 Other Notes Payable Other Notes Payable consists of: June 30, 2021 December 31, 2020 On March 25, 2011 the Company issued a term note for $ 300,000 16 June 25, 2011 October 15, 2021 $ 300,000 $ 300,000 On May 16, 2020, the Company was granted a loan from Citizens Bank N.A. in the amount of $ 58,600 The Loan, which was in the form of a Note issued by the Borrower, matures on May 16, 2022 1 58,600 58,600 On January 1, 2021, the Company was granted a second PPP loan from Citizens Bank N.A. in the amount of $ 58,600 The Loan, which was in the form of a Note issued by the Borrower, matures on January 1, 2026 1 58,600 - Insurance policy finance agreements. - 25,987 Total Notes Payable: $ 417,200 $ 384,587 Long-Term Notes Payable consists of: June 30, 2021 December 31, 2020 On July 7, 2020, the Company was advised that the Small Business Administration (SBA) had approved a $ 150,000 30 3.75 731.00 $ 150,000 $ 150,000 Total Long-Term Notes Payable: $ 150,000 $ 150,000

LEASE (Tables)

LEASE (Tables)	6 Months Ended
	Jun. 30, 2021
Lease
SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES	The Company recognized the following related to a lease in its unaudited consolidated balance sheet at June 30, 2021 and December 31, 2020: SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES June 30, 2021 December 31, 2020 Operating Lease ROU Assets $ 102,146 $ 124,183 Operating Lease ROU Assets $ 102,146 $ 124,183 Operating Lease Liabilities Current portion 45,746 44,623 Long-term portion $ 54,395 $ 77,008 Operating Lease Liabilities $ 100,141 $ 121,631

SEGMENT REPORTING, GEOGRAPHIC_2

SEGMENT REPORTING, GEOGRAPHICAL INFORMATION (Tables)	6 Months Ended
	Jun. 30, 2021
Segment Reporting [Abstract]
SCHEDULE OF BUSINESS SEGMENTS INFORMATION	The Company operates in two business segments SCHEDULE OF BUSINESS SEGMENTS INFORMATION Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Revenue: Vycor Medical $ 462,318 $ 218,997 $ 725,032 $ 526,284 NovaVision $ 29,109 $ 25,269 $ 62,144 $ 48,221 $ 491,427 $ 244,266 $ 787,176 $ 574,505 Gross Profit Vycor Medical $ 424,261 $ 201,179 $ 660,194 $ 472,036 NovaVision $ 27,838 $ 22,594 $ 59,177 $ 44,682 $ 452,099 $ 223,773 $ 719,371 $ 516,718 June 30, December 31, 2021 2020 Total Assets: Vycor Medical $ 1,036,954 $ 953,730 NovaVision 26,812 32,213 Discontinued operations 506 577 Total Assets $ 1,064,272 $ 986,520
SUMMARY OF GEOGRAPHIC INFORMATION	The Company operates in two geographic segments, the United States and Europe. Discontinued operations were part of NovaVision and revenues and assets were in Europe; see Note 3. Set out below are the revenues, gross profits and total assets for each segment. SUMMARY OF GEOGRAPHIC INFORMATION Three Months Ended June 30, Six Months Ended June 30, 2021 2020 2021 2020 Revenue: United States $ 487,908 $ 241,325 $ 776,689 $ 569,140 Europe $ 3,519 $ 2,941 $ 10,487 $ 5,365 $ 491,427 $ 244,266 $ 787,176 $ 574,505 Gross Profit United States $ 448,611 $ 220,832 $ 708,982 $ 511,353 Europe $ 3,488 $ 2,941 $ 10,389 $ 5,365 $ 452,099 $ 223,773 $ 719,371 $ 516,718 June 30, December 31, 2021 2020 Total Assets: United States $ 1,054,002 $ 980,239 Europe 9,764 5,704 Discontinued operations 506 577 Total Assets $ 1,064,272 $ 986,520

EQUITY (Tables)

EQUITY (Tables)	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
SCHEDULE OF STOCK OPTIONS	The details of the outstanding stock options are as follows: SCHEDULE OF STOCK OPTIONS Weighted average Number of shares exercise price Outstanding at December 31, 2020 680,000 $ 0.28 Granted - - Exercised - - Cancelled or expired (680,000 ) - Outstanding at June 30, 2021 - $ -

CONCENTRATION (Tables)

CONCENTRATION (Tables)	6 Months Ended
	Jun. 30, 2021
Risks and Uncertainties [Abstract]
SCHEDULE OF CONCENTRATION	Vycor Medical sells its neurosurgical devices in the US primarily direct to hospitals, and internationally through distributors who in turn sell to hospitals. SCHEDULE OF CONCENTRATION Sales Concentration: Three Months Ended June 30, 2021 2020 Number of customers over 10% - - Percentage of sales 0 % 0 % Six Months Ended June 30, 2021 2020 Number of customers over 10% - 1 Percentage of sales 0 % 19 % Accounts Receivable Concentration At June 30, At December 31, 2021 2020 Number of customers over 10% 0 2 Percentage of accounts receivable 0 % 10 %

BASIS OF PRESENTATION (Details

BASIS OF PRESENTATION (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Entity Listings [Line Items]
Net loss	$ 9,374	$ 248,887	$ 252,293	$ 423,835
Working capital deficiency	604,136		604,136
Related party liabilities	1,870,806		1,870,806
EuroAmerican Investment Corp [Member]
Entity Listings [Line Items]
Term note	300,000		300,000
Accrued interest	$ 352,699		$ 352,699
Maturity date			Oct. 15, 2021

SCHEDULE OF COMMON STOCK NOT IN

SCHEDULE OF COMMON STOCK NOT INCLUDED IN CALCULATION OF DILUTED NET LOSS PER SHARE (Details) - shares	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share	4,380,144	6,207,478
Stock Option Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share		680,000
Debentures Convertible into Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share	3,108,092	2,879,521
Preferred shares convertible to common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share	1,272,052	1,272,052
Deferred Compensation, Share-based Payments [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential shares of common stock that are not included in the calculation of diluted net loss per share		1,375,905

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Paycheck Protection Program [Member] | CARES Act [Member]
Schedule of Capitalization, Long-term Debt [Line Items]
Proceeds from loan	$ 58,600	$ 58,600

SCHEDULE OF LOSS FROM DISCONTIN

SCHEDULE OF LOSS FROM DISCONTINUED OPERATIONS (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
Cash	$ 506		$ 506		$ 577
Total Current Assets	506		506		577
TOTAL ASSETS	506		506		577
Accounts payable	134		134		422
Accrued liabilities - Other					3,168
Other current liabilities	(210)		(210)		15
Total Current Liabilities	(76)		(76)		$ 3,605
Revenue		$ 17,864		$ 38,676
Cost of Goods Sold		2,618		4,219
Gross Profit		15,246		34,457
Selling, general and administrative	10,078	43,780	21,647	72,682
Total Operating Expenses	(10,078)	(43,780)	(21,647)	(72,682)
Operating Loss	(10,078)	(28,534)	(21,647)	(38,225)
Loss on foreign currency exchange	(239)	(1,218)	(842)	(1,262)
Total Other Income (Expense)	(239)	(1,218)	(842)	(1,262)
Loss Before Credit for Income Taxes	(10,317)	(29,752)	(22,489)	(39,487)
Credit for income taxes
Loss from discontinued operations, net of tax	$ (10,317)	$ (29,752)	$ (22,489)	$ (39,487)

SUMMARY OF NOTES PAYABLE (Detai

SUMMARY OF NOTES PAYABLE (Details) - USD ($)	Jul. 07, 2020	Jun. 30, 2021	Dec. 31, 2020
Short-term Debt [Line Items]
Total Related Party Notes Payable		$ 320,873	$ 310,873
Total Notes Payable		417,200	384,587
Total Long-term Notes Payable		150,000	150,000
Economic Injury Disaster Loan Program [Member] | CARES Act [Member]
Short-term Debt [Line Items]
Debt instrument, term	30 years
Total Long-term Notes Payable		150,000	150,000
EuroAmerican Investment Corp [Member]
Short-term Debt [Line Items]
Total Notes Payable		300,000	300,000
Citizens Bank [Member] | Paycheck Protection Program [Member] | CARES Act [Member]
Short-term Debt [Line Items]
Total Notes Payable		58,600	58,600
Citizens Bank [Member] | Second Paycheck Protection Program [Member] | CARES Act [Member]
Short-term Debt [Line Items]
Total Notes Payable		58,600
Peter Zachariou [Member]
Short-term Debt [Line Items]
Total Related Party Notes Payable		30,000	30,000
Fountainhead Capital Management Limited [Member]
Short-term Debt [Line Items]
Total Related Party Notes Payable		290,873	280,873
Insurance Policy Finance Agreements [Member]
Short-term Debt [Line Items]
Total Notes Payable			$ 25,987

SUMMARY OF NOTES PAYABLE (Det_2

SUMMARY OF NOTES PAYABLE (Details) (Parenthetical) - USD ($)	Jan. 02, 2021	Jul. 07, 2020	May 16, 2020	Jun. 25, 2018	Mar. 25, 2011	Jun. 30, 2021	Mar. 12, 2021
Economic Injury Disaster Loan Program [Member] | CARES Act [Member]
Short-term Debt [Line Items]
Value of notes issued		$ 150,000
Notes interest rate		3.75%
Debt instrument, periodic payment		$ 731
EuroAmerican Investment Corp [Member] | Extended Maturity [Member]
Short-term Debt [Line Items]
Debt due date						Oct. 15, 2021
EuroAmerican Investment Corp [Member] | Term Note [Member]
Short-term Debt [Line Items]
Value of notes issued					$ 300,000
Notes interest rate					16.00%
Debt due date					Jun. 25, 2011
Citizens Bank [Member] | Paycheck Protection Program [Member] | CARES Act [Member]
Short-term Debt [Line Items]
Value of notes issued			$ 58,600
Notes interest rate			1.00%
Debt due date			May 16, 2022
Debt due date description			The Loan, which was in the form of a Note issued by the Borrower, matures on May 16, 2022 and bears interest at a rate of 1% per annum.
Citizens Bank [Member] | Second Paycheck Protection Program [Member] | CARES Act [Member]
Short-term Debt [Line Items]
Value of notes issued	$ 58,600
Notes interest rate	1.00%
Debt due date	Jan. 1, 2026
Debt due date description	The Loan, which was in the form of a Note issued by the Borrower, matures on January 1, 2026 and bears interest at a rate of 1% per annum.
Peter Zachariou [Member]
Short-term Debt [Line Items]
Value of notes issued				$ 30,000
Notes interest rate				10.00%
Debt due date				Jun. 25, 2022
Fountainhead Capital Management Limited [Member]
Short-term Debt [Line Items]
Value of notes issued							$ 290,873
Notes interest rate							10.00%
Debt due date description							The Notes will be due between December 2021 and July 2022 or on demand by the Payee.

NOTES PAYABLE (Details Narrativ

NOTES PAYABLE (Details Narrative) - USD ($)	Jun. 30, 2021	Jan. 31, 2018
EuroAmerican Investment Corp [Member]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Debt conversion shares issued	3,108,092
EuroAmerican Investment Corp [Member]
Discounted Future Net Cash Flows Relating to Proved Oil and Gas Reserves [Line Items]
Note payable other		$ 300,000
Conversion price		$ 0.21

SCHEDULE OF SUPPLEMENTAL BALANC

SCHEDULE OF SUPPLEMENTAL BALANCE SHEET INFORMATION RELATED TO LEASES (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Lease
Operating Lease ROU Assets	$ 102,146	$ 124,183
Operating Lease ROU Assets	102,146	124,183
Current portion	45,746	44,623
Long-term portion	54,395	77,008
Operating Lease Liabilities	$ 100,141	$ 121,631

SCHEDULE OF BUSINESS SEGMENTS I

SCHEDULE OF BUSINESS SEGMENTS INFORMATION (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Segment Reporting Information [Line Items]
Revenue	$ 491,427	$ 244,266	$ 787,176	$ 574,505
Gross Profit	452,099	223,773	719,371	516,718
Total Assets	1,064,272		1,064,272		$ 986,520
Discontinued Operations [Member]
Segment Reporting Information [Line Items]
Total Assets	506		506		577
Vycor Medical [Member]
Segment Reporting Information [Line Items]
Revenue	462,318	218,997	725,032	526,284
Gross Profit	424,261	201,179	660,194	472,036
Total Assets	1,036,954		1,036,954		953,730
NovaVision [Member]
Segment Reporting Information [Line Items]
Revenue	29,109	25,269	62,144	48,221
Gross Profit	27,838	$ 22,594	59,177	$ 44,682
Total Assets	$ 26,812		$ 26,812		$ 32,213

SUMMARY OF GEOGRAPHIC INFORMATI

SUMMARY OF GEOGRAPHIC INFORMATION (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020	Dec. 31, 2020
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	$ 491,427	$ 244,266	$ 787,176	$ 574,505
Gross Profit	452,099	223,773	719,371	516,718
Total Assets	1,064,272		1,064,272		$ 986,520
Discontinued Operations [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Total Assets	506		506		577
UNITED STATES
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	487,908	241,325	776,689	569,140
Gross Profit	448,611	220,832	708,982	511,353
Total Assets	1,054,002		1,054,002		980,239
Europe [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Revenue	3,519	2,941	10,487	5,365
Gross Profit	3,488	$ 2,941	10,389	$ 5,365
Total Assets	$ 9,764		$ 9,764		$ 5,704

SCHEDULE OF STOCK OPTIONS (Deta

SCHEDULE OF STOCK OPTIONS (Details) - $ / shares	6 Months Ended
	Jun. 30, 2021	Dec. 31, 2020
Equity [Abstract]
Number of shares Options Outstanding, Ending Balance		680,000
Weighted average exercise price per share Options, Outstanding, Ending balance		$ 0.28
Number of shares Options, Granted
Weighted average exercise price per share Options, Granted
Number of shares Options, Exercised
Weighted average exercise price per share Options, Exercised
Number of shares Options, Cancelled or expired	(680,000)
Weighted average exercise price per share Options, Cancelled or expired

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($)	Apr. 02, 2021	Jan. 31, 2021	Jun. 30, 2021	Jun. 30, 2020
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture
Fountainhead [Member] | Fountainhead Consulting Agreement [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Number of common stock issued			1,071,428	1,071,428
Number of common stock issued, value			$ 175,895	$ 225,000
Directors Deferred Compensation Plan [Member]. | Oscar Bronsther [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Number of common stock issued		466,794
Non-employee Directors [Member] | Directors Deferred Compensation Plan [Member].
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture			99,999	199,998
Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture			$ 21,000	$ 42,000
Steve Girgenti [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Deferred Compensation Arrangement with Individual, Shares Issued	575,649
Lowell Rush [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Deferred Compensation Arrangement with Individual, Shares Issued	566,793
Consultant [Member] | Ricardo Komotar [Member] | Consulting Agreement [Member]
Deferred Compensation Arrangement with Individual, Postretirement Benefits [Line Items]
Number of common stock issued	101,663

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Non-employee Directors [Member] | Directors Deferred Compensation Plan [Member].
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expense related to unissued stock	$ 0	$ 42,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	0
Non-employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Payment Arrangement, Expense	$ 201,927	$ 266,999

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)	Oct. 31, 2016	Jun. 30, 2012	Jun. 30, 2021	Jun. 30, 2020
Product Liability Contingency [Line Items]
Rent expense			$ 38,954	$ 39,349
Trade tax reduced	$ 82,000	$ 82,000
Interest expenses	13,200	13,200
Euro Currency [Member]
Product Liability Contingency [Line Items]
Trade tax reduced	75,000	75,000
Interest expenses	$ 12,000	$ 12,000
GERMANY
Product Liability Contingency [Line Items]
Rent expense			1,815
GERMANY | Euro Currency [Member]
Product Liability Contingency [Line Items]
Rent expense			1,650
Office Space [Member]
Product Liability Contingency [Line Items]
Rent expense			4,000
Other charges			$ 1,500
Lease description			The lease terminated September 30, 2020 and was extended for a further three years to August 31, 2023.

CONSULTING AND OTHER AGREEMEN_2

CONSULTING AND OTHER AGREEMENTS (Details Narrative) - USD ($)	Apr. 02, 2021	Mar. 30, 2021	Jun. 30, 2021	Jun. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock option cash			$ 201,927	$ 266,999
General Consultancy [Member] | Ricardo J Komotar M D [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Shares issued for services		304,989
Milestones [Member] | Ricardo J Komotar M D [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of common stock issued	101,663
Shares issued for services		1,219,957
Fountainhead Consulting Agreement [Member] | Fountainhead [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of common stock issued			1,071,428	1,071,428
Number of common stock issued, value			$ 175,895	$ 225,000
Fountainhead Consulting Agreement [Member] | January 1, 2021 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Stock option cash			$ 5,000
Number of common stock issued			535,714
Common stock exercise price			$ 0.21
Amended Agreement [Member] | Fountainhead [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of common stock issued			1,071,428	1,071,428
Number of common stock issued, value			$ 175,895	$ 225,000
Amended Agreement [Member] | January 1, 2021 [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of common stock issued, value			$ 112,500	$ 225,000

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Related Party Transaction [Line Items]
Accrued dividends			$ 162,185	$ 162,185
Related party transaction amount			$ 0	$ 0
Amended Agreement [Member] | Fountainhead [Member]
Related Party Transaction [Line Items]
Stock Issued During Period, Shares, New Issues			1,071,428	1,071,428
Stock Issued During Period, Value, New Issues			$ 175,895	$ 225,000
Fountainhead [Member]
Related Party Transaction [Line Items]
Accrued dividends			113,019	113,019
Fountainhead [Member] | Unsecured Loan [Member]
Related Party Transaction [Line Items]
Unsecured loan notes issued			$ 10,000	$ 80,000
Unsecured loan notes interest rate	10.00%	10.00%	10.00%	10.00%
Unsecured loan maturity description			due on demand or by their one-year anniversary	due on demand or by their one-year anniversary
Fountainhead [Member] | Directors [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage	58.60%		58.60%
Fountainhead [Member] | Directors [Member] | Series D Preferred Stock [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage	70.00%		70.00%
Peter Zachariou [Member]
Related Party Transaction [Line Items]
Accrued dividends			$ 41,693	$ 41,693
Peter Zachariou [Member] | Series D Preferred Stock [Member]
Related Party Transaction [Line Items]
Equity Method Investment, Ownership Percentage	26.00%		26.00%

SCHEDULE OF CONCENTRATION (Deta

SCHEDULE OF CONCENTRATION (Details) - Customer Concentration Risk [Member] - Segment	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Revenue Benchmark [Member]
Concentration Risk [Line Items]
Number of customers over 10%				1
Revenue Benchmark [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	0.00%	0.00%	0.00%	19.00%
Accounts Receivable [Member]
Concentration Risk [Line Items]
Number of customers over 10%			0	2
Accounts Receivable [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage			0.00%	10.00%

CONCENTRATION (Details Narrativ

CONCENTRATION (Details Narrative) - Purchase [Member] - Customer Concentration Risk [Member]	6 Months Ended
	Jun. 30, 2021
Manufacturer One [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%
Manufacturer Two [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%
Manufacturer Three [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%